In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I.
- In the news
In vivo CAR T-cell therapy KLN-1010 achieved a 100% overall response rate in all 18 multiple myeloma patients in a Phase I trial.
- Why it matters: This work addresses the critical need for effective treatments in multiple myeloma, where current options often leave residual disease.
- What they did: The study involved administering KLN-1010, an in vivo CAR T-cell therapy, to 18 patients, with all showing a response and no minimal residual disease detected after one month.
- The result: The findings suggest KLN-1010 has strong potential for clinical use, enabling complete responses and paving the way for further development in multiple myeloma treatment.